Home Cart Sign in  
Chemical Structure| 127903-20-2 Chemical Structure| 127903-20-2

Structure of 6-(Fmoc-amino)-1-hexanol
CAS No.: 127903-20-2

Chemical Structure| 127903-20-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 127903-20-2 ]

CAS No. :127903-20-2
Formula : C21H25NO3
M.W : 339.43
SMILES Code : OCCCCCCNC(OCC1C2=CC=CC=C2C3=CC=CC=C13)=O
MDL No. :MFCD00380196
InChI Key :VGXOJZUTHIGHPT-UHFFFAOYSA-N
Pubchem ID :2736486

Safety of [ 127903-20-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Computational Chemistry of [ 127903-20-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 25
Num. arom. heavy atoms 12
Fraction Csp3 0.38
Num. rotatable bonds 10
Num. H-bond acceptors 3.0
Num. H-bond donors 2.0
Molar Refractivity 98.98
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

58.56 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

3.6
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

3.8
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

4.08
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

3.1
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

4.34
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

3.78

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-4.03
Solubility 0.0314 mg/ml ; 0.0000925 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-4.72
Solubility 0.00641 mg/ml ; 0.0000189 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-6.92
Solubility 0.0000406 mg/ml ; 0.00000012 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Poorly soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

Yes
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

Yes
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

Yes
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.67 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<2.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

3.59

Application In Synthesis of [ 127903-20-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 127903-20-2 ]

[ 127903-20-2 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 51747-24-1 ]
  • [ 127903-20-2 ]
  • [ 128745-89-1 ]
  • 2
  • [ 127903-20-2 ]
  • [ 166108-25-4 ]
  • Acetic acid (2R,3R,4R,5R,6R)-2-acetoxymethyl-5-azido-6-[6-(9H-fluoren-9-ylmethoxycarbonylamino)-hexyloxy]-4-((2R,3R,4S,5S,6R)-3,4,5-triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-3-yl ester [ No CAS ]
  • [ 189108-72-3 ]
  • 3
  • [ 524-38-9 ]
  • [ 127903-20-2 ]
  • [ 209115-36-6 ]
  • 4
  • [ 4048-33-3 ]
  • [ 28920-43-6 ]
  • [ 127903-20-2 ]
YieldReaction ConditionsOperation in experiment
98% With sodium carbonate; In 1,4-dioxane; at 0 - 25℃; for 12h; 1) Dissolve 5.3 g of fluorenyl methoxycarbonyl chloride in 40 mL of 1,4-dioxane, Add 2g of 6-amino-1-hexanol at 0C, Fully dissolve, then slowly add 20mL of 10% Na2CO3 solution, Reaction at 25 for 12h, The product was extracted with methanol-dichloromethane (methanol, dichloromethane volume ratio 1:19), Combine the organic phases, spin dry the solvent on a rotary evaporator, Use a mixed solvent (consisting of dichloromethane, ethyl acetate and petroleum ether in a volume ratio of 1:3:6) Obtained (yield: 98%);
97% With sodium carbonate; In 1,4-dioxane; water; at 0 - 20℃; for 1h; Fmoc-6-aminohexanol (3). 6-Amino-hexan-1-ol (1.5 g, 12 mmol) was added to a vigorously stirred solution of Na2CO3 in H2O at 0 C. Dioxane (30 mL) was added, providing an opaque mixture. A solution of FmocCl, in dioxane (36 mL) was added dropwise at 0 C. The mixture was then allowed to warm to room temperature and was stirred for 1 hour. AcOEt (300 mL) was added, followed by HCl 0.1M (200 mL). The organic layer was washed with H2O (200 mL) and brine (50 mL), then dried over Na2SO4, filtered and concentrated. The crude product was purified by flash chromatography (CH2Cl2/MeOH, 97:3 to 90:10) to afford 3 as a white solid (3.95 g, 97%).
  • 5
  • [ 127903-20-2 ]
  • [ 290308-57-5 ]
  • [ 290308-58-6 ]
  • 6
  • [ 61198-91-2 ]
  • [ 127903-20-2 ]
  • 6-N-(9-fluorenylmethoxycarbonyl)aminohexyl (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1->4)-2,3,6-tri-O-benzoyl-β-D-glucopyranoside [ No CAS ]
  • 8
  • [ 127903-20-2 ]
  • [ 228715-38-6 ]
YieldReaction ConditionsOperation in experiment
85% With sulfur trioxide pyridine complex; [4699] The title compound was prepared from 1 g (2.95mmol) of commercially available 9H-fluoren-9-ylmethyl-(6-hydroxyhexyl)carbamate under standard conditions, by oxidationwith sulphur trioxide-pyridine complex. 840 mg (85%of theory) of the title compound were obtained.[4700] HPLC (Method 12): R,=2.0 min;[4701] LC-MS (Method 1): R,=l.l min; MS (ESipos):rnlz=338 (M+Hr.
46% With tetrapropylammonium perruthenate; 4-methylmorpholine N-oxide; In dichloromethane; at 20℃; for 1h; 4. To a solution of 3 (200 mg, 0.589 mmol) in DCM (7 mL) was added NMO (142 mg, 1.179 mmol), followed by TPAP (10 mg, 0.029 mmol). The reaction was stirred at room temperature for 1 hour. The solvent was removed under reduced pressure. The crude product was purified by filtration through a pad of silica gel (CH2Cl2/MeOH, 95:5) to afford 4 as a white solid (91 mg, 46%).
  • 9
  • C41H41O4N [ No CAS ]
  • [ 127903-20-2 ]
  • 10
  • [ 127903-20-2 ]
  • N-(9-fluorenylmethoxycarbonyl)-6-aminohexyl triphosphate [ No CAS ]
YieldReaction ConditionsOperation in experiment
[0261] Synthesis of Fmoc-6-aminohexyltriphosphate: <strong>[127903-20-2]Fmoc-6-aminohexanol</strong> (lg, 2.94 mmol) is coevaporated with anhydrous acetonitrile (2 x 20 ml) and then dissolved in triethyphosphate (10 ml).Phosphorous oxychloride (550 p1, 5.88 mmol) is added to this solution once cooled and stirred for 2 hours. To the reaction mixture, tributylamrnoniurn pyrophosphate (5 equivalents, 15 mniol, 0.5 M solution in anhydrous DMF) is added and stirred for 20 minutes. The solution is quenched with 0.1 M triethylammonium bicarbonate buffer (200 ml, pH 7.5) and adjusted to pH -7.[0262] This solution is loaded on a Sephadex A-25 column and purified using 0.1 M to 1.0 M TEAB buffer(pH 7.0) gradient. The appropriate fractions are pooled and further purified on HPLC to provide puretriphosphate, 31P-NMR (D20) -10,5 (d, 2P), -22.84 (t, 1P).
The azide-linker-modified nucleoside hexaphosphate of compound (2) (dT6P-N3) is prepared following the general reaction scheme depicted in FIG. 1. This general reaction scheme can be used for modifying any nucleosidehexaphosphate compound, dN6P, with a hexylamine linker and an azide group.Briefly, 6-Fmoc-aminohexanol (ig, 2.94 mmol) (1 in FIG. 1) is coevaporated with anhydrous acetonitrile (2x 20 ml) and then dissolved in triethyl phosphate (10 ml). To this cooled and stirred solution is added fresh, distilled phosphorous oxychloride (550 p1, 5.88 mmol) and the mixture is stirred for 2 hr at 0C. Tributylammonium pyrophosphate (5 eq., 15 mmol, 0.5 M solution in anhydrousDMF) and tributylamine (15 mmol) is added and this mixture stirred for 20 mm.The solution is quenched with 0.1 M triethylammonium bicarbonate buffer (TEAB,200 ml, pH7.5) and adjusted to pH -7. This solution is loaded on a Sephadex A25 column and eluted using 0.1 M to 1.0 M TEAB buffer (pH 7.0) gradient. Theappropriate fractions are collected, pooled, and further purified on reverse phaseHPLC on SupelcosilTM LC-18-T (Supelco) 3 pM, 15 cm X 4.6 mm. (HPLC parameters: Mobile phase: A, 8.6 mM Et3N, 100 mM HFIP in water at pH 8.1; B,100% methanol. Started from 100% A 0% B to 0% A 100% B in 40 minutes.)The pure triphosphate, 31P-NMR (D20) exhibits following shifts: 6: -7.68 (d, 1P), -10.5 (d, 1P), -22.65 (t, 1P). The Fmoc-aminohexyltriphosphate produced (200 mg,0.35 mmol) (2 in FIG. 1) is coevaporated with anhydrous acetonitrile (2X 10 ml) and then dissolved in anhydrous DMF (3 ml). CDI (4 eq., 1.4 mmol) is added and the solution stirred at room temperature for 4 h. Methanol (6 eq., 85 p1) is added with further stirring for 30 mm. To the above product (3), a solution of the desired 2’-deoxynucleoside-5’-triphosphate (dNTP, tributylammonium salt, 0.5 mmol) inDMF and MgCI2 (10 equivalents, 3.5 mmol) is added. This reaction mixture is stirred for 18 h followed by the addition of 10% triethylamine in water (25 ml) to hydrolyze the Fmoc group and yield the desired linker-modified nucleotide hexaphosphate compound, dN6P-NH2 (4-7 in FIG. 1). The reaction mixture is stirred further for 16 h and the precipitated solid is filtered and the solutionextracted with ether. The aqueous layer is concentrated and purified on reverse phase HPLC (SupelcosilTM LC-C18-T (Sulpelco) 3.0 pm particle size, 15 cm X 4.6 mm) using the following parameters: 100% A 0% B in 4 mm, then linear gradient change to 70% A 30% B for 30 minutes, and finally 0% A and 100% B for another 45 mm at room temperature at a flow rate of 1 mI/mm; mobile phase: A, 0.1 MTEAA; B, 100% ACN). The dN6P-NH2 product can be characterized by 31P-NMR based on the following shifts: 6-10.63 (bs, 1P), -11.65 (bs, 1P), -23.35 (bm. 4P). MALDI-TOF MS for the four commonly used linker-modified dN6P compounds:dA6P-NH2: 832.02 (calculated 829); dT6P-NH2: 825.97 (calculated 820); dG6P-NH2: 848.33 (calculated 845); dC6P-NH2: 826.08 (calculated 828.0).
  • 11
  • [ 127903-20-2 ]
  • [ 952661-18-6 ]
  • 12
  • [ 127903-20-2 ]
  • 3-((1-adamantyloxy){1-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-azepanyl}phosphoryl)-2-benzylpropanoic acid [ No CAS ]
  • 13
  • [ 127903-20-2 ]
  • [ 952661-13-1 ]
  • 14
  • [ 127903-20-2 ]
  • C29H30NPO6C2H4(C8H6O)2 [ No CAS ]
  • 15
  • [ 127903-20-2 ]
  • C40H46NPO6C8H6OCH2 [ No CAS ]
  • 16
  • C27H32O5S [ No CAS ]
  • [ 127903-20-2 ]
  • 17
  • C26H29O2N3 [ No CAS ]
  • [ 127903-20-2 ]
  • 18
  • C26H31O2N [ No CAS ]
  • [ 127903-20-2 ]
  • 19
  • [ 629-11-8 ]
  • [ 127903-20-2 ]
  • 20
  • [ 742103-41-9 ]
  • [ 127903-20-2 ]
  • 21
  • [ 127903-20-2 ]
  • C54H86N2O15 [ No CAS ]
  • 22
  • [ 127903-20-2 ]
  • 33-[4-(6-amino-hexylamino)-3,5-dihydroxy-6-methyl-tetrahydro-pyran-2-yloxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14-oxa-bicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid [ No CAS ]
  • 23
  • [ 127903-20-2 ]
  • C69H96N2O18 [ No CAS ]
  • 24
  • [ 127903-20-2 ]
  • 33-{4-[6-(9<i>H</i>-fluoren-9-ylmethoxycarbonylamino)-hexylamino]-3,5-dihydroxy-6-methyl-tetrahydro-pyran-2-yloxy}-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14-oxa-bicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid [ No CAS ]
  • 25
  • [ 127903-20-2 ]
  • [ 432546-41-3 ]
  • 26
  • [ 127903-20-2 ]
  • C68H94N2O19 [ No CAS ]
  • 27
  • [ 127903-20-2 ]
  • [ 432546-40-2 ]
  • 28
  • [ 127903-20-2 ]
  • Acetic acid (2R,3R,4R,5R,6S)-2-acetoxymethyl-5-amino-6-[6-(9H-fluoren-9-ylmethoxycarbonylamino)-hexyloxy]-4-((2R,3R,4S,5S,6R)-3,4,5-triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-3-yl ester [ No CAS ]
  • 29
  • [ 127903-20-2 ]
  • [ 189108-76-7 ]
  • 30
  • [ 127903-20-2 ]
  • C30H52N4O13S [ No CAS ]
  • 31
  • [ 127903-20-2 ]
  • Acetic acid (2R,3R,4R,5R,6S)-2-acetoxymethyl-5-acetylamino-6-(6-amino-hexyloxy)-4-((2R,3R,4S,5S,6R)-3,4,5-triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-3-yl ester [ No CAS ]
  • 32
  • [ 127903-20-2 ]
  • C42H64N4O19S [ No CAS ]
  • 33
  • [ 88574-06-5 ]
  • [ 127903-20-2 ]
  • 34
  • [ 19120-62-8 ]
  • [ 127903-20-2 ]
  • [ 134939-09-6 ]
  • 35
  • [ 68114-30-7 ]
  • [ 127903-20-2 ]
  • [ 134939-08-5 ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 127903-20-2 ]

Alcohols

Chemical Structure| 209115-32-2

A731483 [209115-32-2]

(9H-Fluoren-9-yl)methyl (4-hydroxybutyl)carbamate

Similarity: 0.98

Chemical Structure| 147190-31-6

A641180 [147190-31-6]

(9H-Fluoren-9-yl)methyl (6-hydroxy-5-(hydroxymethyl)hexyl)carbamate

Similarity: 0.97

Amides

Chemical Structure| 118119-32-7

A924093 [118119-32-7]

(9H-Fluoren-9-yl)methyl (5-aminopentyl)carbamate

Similarity: 0.98

Chemical Structure| 209115-32-2

A731483 [209115-32-2]

(9H-Fluoren-9-yl)methyl (4-hydroxybutyl)carbamate

Similarity: 0.98

Chemical Structure| 296247-94-4

A528952 [296247-94-4]

Bis((9H-fluoren-9-yl)methyl) hexane-1,6-diyldicarbamate

Similarity: 0.98

Chemical Structure| 147190-31-6

A641180 [147190-31-6]

(9H-Fluoren-9-yl)methyl (6-hydroxy-5-(hydroxymethyl)hexyl)carbamate

Similarity: 0.97

Chemical Structure| 945923-91-1

A441360 [945923-91-1]

(9H-Fluoren-9-yl)methyl (6-aminohexyl)carbamate hydrochloride

Similarity: 0.97

Amines

Chemical Structure| 118119-32-7

A924093 [118119-32-7]

(9H-Fluoren-9-yl)methyl (5-aminopentyl)carbamate

Similarity: 0.98

Chemical Structure| 209115-32-2

A731483 [209115-32-2]

(9H-Fluoren-9-yl)methyl (4-hydroxybutyl)carbamate

Similarity: 0.98

Chemical Structure| 296247-94-4

A528952 [296247-94-4]

Bis((9H-fluoren-9-yl)methyl) hexane-1,6-diyldicarbamate

Similarity: 0.98

Chemical Structure| 147190-31-6

A641180 [147190-31-6]

(9H-Fluoren-9-yl)methyl (6-hydroxy-5-(hydroxymethyl)hexyl)carbamate

Similarity: 0.97

Chemical Structure| 945923-91-1

A441360 [945923-91-1]

(9H-Fluoren-9-yl)methyl (6-aminohexyl)carbamate hydrochloride

Similarity: 0.97